ARTICLE | Clinical News

MG98: Phase I data; Phase II

November 20, 2000 8:00 AM UTC

Interim results from Phase I dose escalation trials showed that 1 patient with renal cell cancer had a partial response lasting >9 months, and 2 mesothelioma patients had stable disease lasting 6 and 14 months, respectively. The compound was well tolerated, with transient side effects including fatigue, anorexia, fever and chills, and elevated liver enzymes. Data were presented at the New Drugs in Cancer Therapy meeting in Amsterdam. The product is partnered with MGI Pharma Inc. (MOGN, Minneapolis, Minn.). ...